Table 1 Clinical features of pSS patients and controls

Sex, female/male

54/2

17/2

0.244

Age, y

49.3 ± 14.0

53.1 ± 11.9

0.292

Disease duration, mo, M(P₂₅ ~ P₇₅)

33(26–41)

13(9–16)

0.080

Anti-Ro/52 antibody, n(%)

43(76.8)

2(10.5)

< 0.001

Anti-Ro/60 antibody, n(%)

31(55.4)

3(15.8)

0.003

Anti-La/SSB antibody, n(%)

19(33.9)

1(5.3)

0.015

RF,O-20IU/mL

49.1 ± 49.14

11.63 ± 12.62

< 0.001

ANA ≥ 1:80, n(%)

47(83.9)

3(15.8)

< 0.001

lgG,7–16 g/L

17.37 ± 6.51

11.95 ± 2.69

0.001

lgA,0.4–2.8 g/L

3.03 ± 1.83

2.42 ± 4.51

0.001

lgM,0.7-3.0 g/L

1.73 ± 1.81

1.09 ± 0.76

0.128

C3,0.88–2.01 g/L

0.94 ± 0.24

1.01 ± 0.23

0.281

C4,0.16–0.47 g/L

0.22 ± 0.10

0.28 ± 0.06

0.010

Serum Globulin,15–35 g/L

34.75 ± 9.03

27.01 ± 4.29

0.001

ESR, 0–20 mm/h

29.79 ± 27.59

11.47 ± 6.82

< 0.001

CRP, 0–6 mg/L

7.18 ± 10.76

5.34 ± 5.55

0.342

Schirmer ≤ 5 mm/5 min (%)

30(53.6)

12(63.2)

0.555

ESSDAI score

8.88 ± 6.19

NA

-

ESSPRI score

3.29 ± 1.10

NA

-